Lupus Nephritis CONTROLLED.
Lumira Ventures partners with exceptional entrepreneurs to build
life science companies that transform the lives of patients worldwide
Aurinia Pharmaceuticals
Improving patients lives
(Nasdaq: AUPH, TSX: AUP)
Epileptic Seizures STOPPED.
Lumira Ventures partners with exceptional entrepreneurs to build
life science companies that transform the lives of patients worldwide
Engage Therapeutics
Acquired by UCB
Cancer Treatment TARGETED.
Lumira Ventures partners with exceptional entrepreneurs to build
life science companies that transform the lives of patients worldwide
Zymeworks
Building Better Biologics
(NYSE: ZYME)
Hepatitis C CURED. Pharmasset
Acquired by Gilead Sciences
$11.2B
Lumira Ventures partners with exceptional entrepreneurs to build
life science companies that transform the lives of patients worldwide
Cancer Treatment AUGMENTED.
Lumira Ventures partners with exceptional entrepreneurs to build
life science companies that transform the lives of patients worldwide
G1 Therapeutics
The immune system preserved
(Nasdaq: GTHX)
Hip and Knee Surgery ROBOT
ICIZED.
Mako Surgical
Acquired by Stryker
$1.65B
Lumira Ventures partners with exceptional entrepreneurs to build
life science companies that transform the lives of patients worldwide
Moderate and
Severe Asthma
TRANS
FORMED.
Ception
Acquired by Cephalon
$550 million
Lumira Ventures partners with exceptional entrepreneurs to build
life science companies that transform the lives of patients worldwide

Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.

Lumira News

Canada’s Edesa Biotech in Frontlines of COVID-19 Treatment Race.

September 20, 2020
As COVID-19 continues its destructive path as the most formidable global pandemic in a century, pharmaceutical companies around the globe are racing to develop drug treatments to mitigate the... Learn More

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio

August 27, 2020
Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis August 24, 2020 06:59 AM Eastern Daylight Time NEW YORK... Learn More

G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer

August 17, 2020
- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration- Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust... Learn More

HistoSonics Announces $40 Million Financing

June 8, 2020
Breakthrough medical platform offers vision of non-invasive procedures to eliminate diseased tissues and tumors MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- HistoSonics, developer of a... Learn More

Team Lumira

Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.

MEET THE TEAM
Image

Philanthropy

Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.

LEARN MORE
  • “Lumira’s philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael’s ability to accelerate the pace.”

    Dr. Arthur Slutsky | Vice-President
    Vice-President of Research at St. Michael’s Hospital
  • “Lumira’s model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation.”

    Barbara Grantham | President & Ceo
    VGH & UBC Hospital Foundation
  • “This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”

    Paul Alofs | President & Ceo
    Princess Margaret Cancer Foundation

Contact Us

Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.

Image

Toronto

141 Adelaide Street
Suite 770
Toronto, ON
Canada, M5H 3L5
416.213.4223

Image

Montreal

Espace CDPQ
3, Place Ville Marie
Bureau 12350, Niveau L
Montreal, QC
Canada, H3B 0E7
514.844.6927

Image

Vancouver

1021 West Hastings Street,
9th floor
Vancouver, BC
Canada, V6E 0C3
604.558.5156

Image

Boston

303 Wyman Street
Suite 300
Waltham, MA,
USA, 02451-1208
781.530.3868